Who was studied?
51 patients enrolled; 42 underwent tumor assessment by October 31, 2022.
What does the publication report?
ORR 21.4%, DCR 61.9%; median PFS 5.8 months and OS 13.5 months.
Safety findings
Four grade ≥3 treatment-related events; three patients discontinued all study treatment.
How should we interpret it?
Uncontrolled interim conference evidence, linked to NCT04892498 rather than counted as a separate trial. The abstract’s total adverse-event count and percentage are inconsistent; that percentage is not reproduced.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
PD-1 inhibitors combined with radiotherapy and GM-CSF, sequentially followed by IL-2 (PRaG 2.0) regimen in advanced refractory solid tumors: A prospective, multicenter, single-arm clinical trial. · DOI: 10.1200/JCO.2023.41.16_suppl.2603
Other publications from this study
- PD-1 inhibitors combined with radiotherapy and GM-CSF, sequentially followed by IL-2 regimen in advanced refractory solid tumors: a prospective, multicenter clinical trial.
- PRaG 2.0: the 2023 ASTRO conference report
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.